Infinimmune, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Infinimmune, Inc. - overview
Established
2022
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Founded in 2022 by Wyatt McDonnell (CEO), Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe, and based in California, US, Infinimmune, Inc. operates as a biotechnology research company that develops new methods for antibody drug discovery and development. In December 2022, Infinimmune, Inc. raised USD 12 million in Seed funding led by investor Playground Ventures, with participation from Axial VC, Civilization Ventures, and Pear VC.
The firm develops antibody-based drugs that address unmet medical needs by screening human samples containing B cells and reading and rewriting the antibody sequences present to create superior drug candidates. The company uses large datasets and sample cohorts to discover new targets and create new classes of secure and efficient antibody drugs. The company intends to use the December 2022 funding to accelerate its platform in product research and development.
Current Investors
Pear VC, Playground Ventures, Civilization Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.infinimmune.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.